Catrin Pritchard's Recent Publications

Publications since 2010

 

  • Vitecchie G, Powley I, Demetriou C, Cooper J, Butterworth M, Patel M, Abid N, Miles G, Howells L, Pringle H, MacFarlane M, Pritchard C (2021) Patient-derived tumour explants as a “live” preclinical platform for predicting drug resistance in patients. Journal of Visualised Experiments. DOI: 10.3791/62130
  • Maeda Y, Tidyman WE, Ander BP, Pritchard CA, Rauen KA (2021) RAS/MAPK Dysregulation in development causes a skeletal myopathy in an activating BrafL597V mouse model for Cardio-facio-cutaneous syndrome. Dev Dynamics DOI: 10.1002/dvdy.309
  • Crezee T, Tesselaar M, Nagarajah J, Corver W, Morreau J, Pritchard C, Kimura S, Kuiper J, van Engen-van Grusven I, Smit J, Metea-Maier R, Plantinga T (2021) Digoxin treatment reactivates in vivo thyroid-specific radioactive iodide uptake and correlates with favorable clinical outcome in non-meduallary thyroid cancer. Cellular Oncology DOI: 10.1007/s13402-021-00588-y
  • Collins A, Miles GJ, Powley IR, Hew R, Pringle JH, MacFarlane M, Pritchard C, Moss EL (2021) Development of a patient-derived explant model for prediction of drug responses in endometrial cancer. Gynaecology Oncology DOI: 10.1016/j.ygyno.2020.11.033
  • Zhang M, Sun QQ, Harber J, Dawson A, Luo J-L, Nakas A, Busacca S, Sharkey A, Waller D, Sheaff MT, Richards C, Wells-Jordan P, Gaba A, Poille C, Baitei EY, Bzura A, Dzialo J, Jama M, Le Quesne J, Bajaj A, Martinson L, Shaw J, Pritchard C, Kamata T, Kuse N, Brannan L, Zhang P, Yang H, Griffiths G, Wilson G, Swanton C, Dudbridge F, Hollox EJ, Fennell DA (2021) Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nature Communications 12: 1751.
  • Miles GJ, Powley I, Mohammed S, Howells L, Pringle H, Hammonds T, MacFarlane M, Pritchard C (2020). Evaluating and comparing immunostaining and computational methods for spatial profiling of drug response in patient-derived explants. Laboratory Investigation 101: 396-407.
  • Kamata T, So TY, Ahmed Q, Giblett S, Patel B, Luo J, Reddel R, Pritchard, C (2020) Fibroblast-derived STC-1 modulates tumour associated macrophages and lung adenocarcinoma development. Cell Reports 31: 107802.
  • Greenhalgh C, Karekla E, Miles G, Powley I, Pritchard C, MacFarlane M, Pringle JH, Managh A (2020) Exploration of matrix effects in laser ablation inductively coupled plasma mass spectrometry imaging of cisplatin-treated tumours. Analytical Chemistry 92: 9847-9855.
  • MacKenzie D, Robertson N, Rather I, Reid C, Sendzikaite G, Cruickshanks H, McBryan T, Pritchard C, Blyth K, Adams PD (2020) DNMT3B has oncogenic activity but evidence suggests that it does not promote CIMP nor cooperate with activated BRAFV600E in human intestinal cancer. iScience DOI: 10.1016/j.isci.2020.100838
  • Al Dujaily E, Baena J, Das M, Sereno M, Smith C, Kamata T, Officer L, Pritchard C, Le Quesne J (2020) Statin use is associated with decreased pro-tumourigenic macrophages within in situ but not invasive regions of human lung adenocarcinomas. JNCI Cancer Spectrum. DOI: 10.1093/jncics/pkz101
  • Collins A, Miles G, Wood J, MacFarlane M, Pritchard C, Moss E (2020) Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer. Gynaecology Oncology. DOI: 10.1016/j.ygyno.2019.11.020.
  • Powley IR, Patel M, Miles G, Pringle H, Howells L, Thomas A, Kettleborough K, Bryans J, Hammonds T, MacFarlane M, Pritchard C (2020) Patient-Derived Explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery. British Journal of Cancer. DOI: 10.1038/s41416-019-0672-6.
  • Rakhit CP, Trigg RM, Le Quesne J, Kelly M, Shaw JA, Pritchard C, Martins LM (2019) Early detection of premalignant lesions in a KRASG12D-driven mouse lung cancer model by monitoring circulating free DNA. Disease Models and Mechanisms.  2019 Feb 12;12(2). pii: dmm036863.
  • Hey F, Andreadi C, Noble C, Patel B, Jin H, Kamata T, Straatman K, Luo J, Balmanno K, Jones DTW, Collins VP, Cook SJ, Caunt CJ, Pritchard C (2018) Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERK. Heliyon 4: e01065.
  • Adamo P, Cowley CM, Neal CP, Mistry V, Page K, Dennison A, Isherwood J, Hastings R, Luo J, Martins LM, Pritchard C, Manson M, Shaw J (2017) Profiling tumour heterogeneity through circulating tumour DNA in patients with Pancreatic Cancer. Oncotarget 8: 87221-87233.
  • Kamata T, Giblett S, Pritchard C (2017) KRASG12D expression in lung-resident myeloid cells promotes pulmonary LCH-like neoplasm sensitive to statin treatment. Blood 130: 514-526.
  • Zou M, Baitei EY, BinEssa H, Al-Mohanna FA, Parhar RS, St-Arnaud R, Kimura S, Pritchard C, Alzahrani AS, Assiri AM, Meyer BF, Shi Y (2017) Cyp24a1 attenuation limits progression of BrafV600E-induced papillary thyroid cancer cells and sensitizes them to BrafV600E inhibitor PLX4720. Cancer Research 77: 2161-2172.
  • Papaioannou G, Petit ET, Liu ES, Baccarini M, Pritchard C, Demay MB (2017) Raf Kinases are Essential for Phosphate Induction of Erk1/2 Phosphorylation in Hypertrophic Chondrocytes and Normal Endochondral Bone Development. Journal of Biological Chemistry 292: 3164-3171.
  • Karekla E, Liao W-J, Sharpe B, Pugh J, Le Quesne J, Moore D, Pritchard C, MacFarlane M, Pringle JH (2017) Ex-vivo explant culture of NSCLC provides a relevant pre-clinical model for evaluation of primary tumour responses to anti-cancer therapies. Cancer Research 77: 2029-2039.
  • Cammareri P, Rose AM, Vincent DF, Wang J, Nagano A, Libertini S, Ridgway RA, Athineos D, Coates PJ, McHugh A, Pourreyron C, Dayal JH, Larsson J, Weidlich S, Spender LC, Sapkota GP, Purdie KJ, Proby CM, Harwood CA, Leigh IM, Clevers H, Barker N, Karlsson S, Pritchard C, Marais R, Chelala C, South AP, Sansom OJ, Inman GJ (2016) Inactivation of TGFb receptors in stem cells drives cutaneous squamous cell carcinoma. Nature Communications 7: 12493.
  • Hey F, Giblett S, Forrest S, Herbert C, Pritchard C (2016) Phosphorylations of serines 21/9 in Glycogen Synthase Kinase a/b are not required for lineage commitment or WNT signaling in the normal mouse intestine. Plos One 11: e0156877.
  • Aguilar Hernandez M, Patel B, Hey F, Giblett S, Davis H, Pritchard C (2016) Regulation of BRAF protein stability by a negative feedback loop involving the MEK-ERK pathway but not the FBXW7 tumour suppressor. Cell Signalling 28: 561-571.
  • Zou M, Baitei EY, Al-Rijjal RA, Parhar RS, Al-Mohanna FA, Kimura S, Pritchard C, Binessa HA, Alzahrani AS, Al-Khalaf HH, Hawwari A, Akhtar M, Assiri AM, Meyer BF, Shi Y (2015) Thyroid stimulating hormone overcomes BrafV600E-induced senescence to promote tumor progression via down-regulation of p53 expression in papillary thyroid cancer. Oncogene 35: 1909-1918.
  • Kamata T, Jin H, Giblett S, Patel B, Patel F, Foster C, Pritchard C (2015) The cholesterol binding protein NPC2 restrains recruitment of stromal macrophage-lineage cells to early-stage mouse lung tumours. EMBO Molecular Medicine 7: 1119-1137.
  • Lenos K, Goos JACM, Vuist IM, den Uil SJ, Delis-van Dieman PM, Belt EJT, Stockmann HBAC, Bril H, de Wit M, Carvalho B, Giblett S, Pritchard CA, Meijer GA, van Kooyk Y, Fijneman RJA, van Vliet SJ (2015) MGL-ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colorectal cancer patients. OncoTarget 6: 26278-26290.
  • Zou M, Baitei EY, Al-Rijjal RA, Parhar RS, Al-Mohanna FA, Kimura S, Pritchard C, BinEssa H, Alanazi AA, Alzahrani AS, Akhtar M, Assiri AM, Meyer BF, Shi Y (2015) KRASG12D mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1. Lab Invest 95: 1269-1277.
  • Althubiti M, Lezina L, Carrera S, Jukes-Jones R, Giblett SM, Antonov A, Barlev N, Saldanha GS, Pritchard CA, Cain K, Macip S (2014) Characterisation of novel markers of senescence and their prognostic potential in cancer. Cell Death and Disease 5:e1528.
  • Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C,
    Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee S-M, Lester J, Kerr K, Muller S, Iles N, Smith S, Murugaesu N, Mitter R, Salm M, Stuart A, Matthews N, Adams H, Ahmad T, Attanoos R, Bennett J, Birkbak NJ, Booton R, Brady G, Buchan K, Capitano A, Chetty M, Cobbold M, Crosbie P, Davies H, Denison A, Djearman M, Goldman J, Haswell T, Joseph L,
    Kornaszewska M, Krebs M, Langman G, MacKenzie M, Millar J, Morgan B, Naidu B, Nonaka D, Peggs K, Pritchard C, Remmen H, Rowan A, Shah R, Smith E, Summers Y, Taylor M, Veeriah S, Waller D, Wilcox B, Wilcox M, Woolhouse I, McGranahan N, Swanton C (2014) Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. PLOS Biology 12: e1001906.
  • Pier DM, Shehatou GSG, Giblett S, Pullar CE, Pritchard CA, Challis RAJ, Mitcheson J (2014) Long-term block is required to inhibit cellular transformation by human ether-a-go-go related gene (hERG1) potassium channels. Molecular Pharmacology 86: 211-221.
  • Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, Athineos D, Kang T-W, Lasitschka F, Andrulis M, Pascual G, Morris J, Khan S, Jin H, Dharmalingam G, Snijders AP, Carroll T, Capper D, Pritchard C, Inman G, Longerich T, Sansom OJ, Benitah SA, Zender L, Gil J (2013) A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nature Cell Biol. 15: 978-990.
  • Kamata T, Dankort D, Kang J, Giblett S, Pritchard C, McMahon M, Leavitt A (2013) Haemopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720. Mol Cancer Res. 11: 1530-1541.
  • Hey F and Pritchard C (2013) A new mode of RAF auto-regulation: a further complication in the inhibitor paradox. Cancer Cell. 23: 561-563.
  • Dyer MJS, Vogler M, Samuel J, Jayne S, Wagner S, Pritchard C and Macip S (2013) Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls. British Journal of Haematology. 160: 725-733.
  • Andreadi CA, Noble C, Patel B, Jin H, Aguilar Hernandez MM, Balmanno K, Cook SJ, Pritchard C (2012) Regulation of MEK/ERK pathway output by subcellular localization of B-Raf. Biochem. Soc. Trans. 40: 67-72.
  • Debrand E, Conti FJ, Bate N, Spence L, Mazzeo D, Pritchard CA, Monkley SJ, Critchley DR (2012) Mice carrying a complete deletion of the talin2 coding sequence are viable and fertile. Biochem Biophys Res Comm 426: 190-195.
  • Andreadi C, Cheung L-K, Giblett S, Patel B, Jin H, Mercer K, Kamata T, Lee P, Williams A, McMahon M, Marais R, Pritchard C (2012) The intermediate-activity L597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes and Development 26: 1945-1958.
  • Stringer EJ, Duluc I, Saandi T, Davidson I, Bialecka M, Sato T, Barker N, Clevers H, Pritchard CA, Winton DJ, Wright NA, Freund JN, Deschamps J, Beck F (2012) Cdx2 determines the fate of postnatal intestinal stem cells. Development 139: 465-474.
  • Franco A, Malaguarnera R, Refetoff S, Liao X-H, Lundsmith E, Kimura S, Pritchard C, Marais R, Davies T, Weinstein L, Chen M, Rosen N, Ghossein R, Knauf J, Fagin J (2011) Thyrotrophin receptor signaling-dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci USA 108: 1615-1620.
  • Kamata T, Pritchard C (2011) Mechanisms of aneuploidy induction by RAS and RAF oncogenes. Am J Cancer Res 1: 955-971.
  • Monkley SJ, Kostourou V, Spence L, Petrich B, Coleman S, Ginsberg MH, Pritchard CA, Critchley DR (2010) Endothelial cell talin1 is essential for embryonic angiogenesis. Dev Biol 349: 494-502.
  • Carragher LAS, Snell KR, Giblett SM, Aldridge VSS, Patel B, Cook SJ, Winton DJ, Marais R, Pritchard CA (2010) V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Molecular Medicine 2: 458-471.
  • Kamata T, Hussain J, Giblett S, Hayward R, Marais R, Pritchard C (2010) BRAF inactivation drives aneuploidy by deregulating CRAF. Cancer Res 70:8475-8486.
  • Kopp PM, Bate N, Hansen TM, Brindle NBJ, Praekelt U, Debrand E, Coleman S, Mazzeo D, Goult BT, Gingras AR, Pritchard CA, Critchley DR, Monkley SJ (2010) Studies on the morphology and spreading of human endothelial cells define key inter- and intramolecular interactions for talin1. European Journal of Cell Biology 89: 661-673.
  • Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumour progression through CRAF. Cell 140: 209-221.
  • Dhomen N, Da Rocha Dias S, Hayward R, Ogilvie L, Hedley D, Delmas V, Henderson D, Springer CJ, Pritchard C, Larue L, Marais R (2010) Inducible expression of V600EBraf using tyrosinase-driven Cre recombinase results in embryonic lethality. Pigment Cell and Melanoma Research. 23: 112-120.

Share this page:

NEWS

Powerful pre-clinical platform for anti-cancer drug and biomarker discovery

Pre-clinical models that can accurately predict outcomes in the clinic are much sort after in the field of cancer drug discovery and development.  Read about how patient derived explants offer many advantages and are the powerful model of choice. A copy of the review, published in the British Journal of Cancer, is available by clicking this link: PDE Platform

---------------------------------

SEND Study Success

Congratulations to Chris Avery, who with collaborating colleagues published findings of the SEND study, a multi-centre randomised trial using two different surgical protocols for mouth cancer treatment.  A nationwide first for this type of trial, using real-world data.  The paper, published in the British Journal of Cancer, is available by clicking this link: SEND Paper

---------------------------------

Centre Health and Wellbeing Group
Join up for a walk on the park Friday lunchtime - details here.

More information from Jenny McNair jm65@le.ac.uk

Contact Details

Leicester Cancer Research Centre
Robert Kilpatrick Clinical Sciences Building
University of Leicester
Leicester Royal Infirmary
Leicester LE2 7LX

T: +44 (0) 116 252 3170
E: cancerstudies@le.ac.uk

(Please note this email address should not be used for clinical referrals or patient correspondence)

Maps and Directions

Sat Nav users: 
LE1 5WW

Accessibility

AccessAble logo

The University of Leicester is committed to equal access to our facilities. DisabledGo has a detailed accessibility guide for the Robert Kilpatrick Clinical Sciences Building.

Seminars

.